Previous Article | Next Article 
Infection and Immunity, May 2000, p. 2587-2593, Vol. 68, No. 5
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Inhibition of Vesicular Secretion in Both Neuronal and
Nonneuronal Cells by a Retargeted Endopeptidase Derivative of
Clostridium botulinum Neurotoxin Type A
John A.
Chaddock,*
John R.
Purkiss,
Lorna M.
Friis,
Janice D.
Broadbridge,
Michael J.
Duggan,
Sarah J.
Fooks,
Clifford C.
Shone,
Conrad P.
Quinn, and
Keith A.
Foster
Centre for Applied Microbiology & Research,
Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom
Received 15 October 1999/Returned for modification 17 December
1999/Accepted 11 January 2000
 |
ABSTRACT |
Clostridial neurotoxins potently and specifically inhibit
neurotransmitter release in defined cell types by a mechanism that involves cleavage of specific components of the vesicle docking/fusion complex, the SNARE complex. A derivative of the type A neurotoxin from
Clostridium botulinum (termed LHN/A) that
retains catalytic activity can be prepared by proteolysis. The
LHN/A, however, lacks the putative native binding domain
(HC) of the neurotoxin and is thus unable to bind to
neurons and effect inhibition of neurotransmitter release. Here we
report the chemical conjugation of LHN/A to an alternative
cell-binding ligand, wheat germ agglutinin (WGA). When applied to a
variety of cell lines, including those that are ordinarily resistant to
the effects of neurotoxin, WGA-LHN/A conjugate potently
inhibits secretory responses in those cells. Inhibition of release is
demonstrated to be ligand mediated and dose dependent and to occur via
a mechanism involving endopeptidase-dependent cleavage of the natural
botulinum neurotoxin type A substrate. These data confirm that the
function of the HC domain of C. botulinum neurotoxin type A is limited to binding to cell surface moieties. The
data also demonstrate that the endopeptidase and translocation functions of the neurotoxin are effective in a range of cell types, including those of nonneuronal origin. These observations lead to the
conclusion that a clostridial endopeptidase conjugate that can be used
to investigate SNARE-mediated processes in a variety of cells has been
successfully generated.
 |
INTRODUCTION |
The clostridial neurotoxin (CNT)
family includes tetanus toxin (TeNT), produced by Clostridium
tetani, and the seven antigenically distinct botulinum neurotoxins
produced from strains of Clostridium botulinum (BoNTs).
These proteins are responsible for the conditions of tetanus and
botulism, respectively, that develop as a direct result of inhibition
of Ca2+-dependent neurotransmitter release, a mechanism of
action common to all the CNTs. In the case of BoNTs, intoxication of
the neuromuscular junction is thought to occur in at least three
phases: an initial binding phase, an internalization phase, and finally
a neurotransmitter blockade phase (24).
All CNTs have a similar structure and consist of a heavy chain (HC:
approximately 100 kDa) covalently joined to a light chain (LC:
approximately 50 kDa) by a single disulfide bond. Proteolytic cleavage
of the HC of C. botulinum neurotoxin type A (BoNT/A) generates two fragments of approximately 50 kDa each. The C-terminal domain (HC) is required for target cell binding, with the
N-terminal domain (HN) being proposed to be involved in
intracellular membrane translocation (22). Under conditions
in which the disulfide bond between the LCs and HCs is maintained,
trypsin cleavage results in a 100-kDa species termed LHN/A
(originally described as H2L [23])
representing a catalytically active, non-cell-binding derivative of
BoNT/A.
The identities of the cellular receptors for CNTs are generally
unknown, though it is clear that CNTs are highly specific for the
neuromuscular junction. It is proposed that CNTs bind to their target
cell by a combination of specific, high-affinity binding events
possibly involving more than one component (9). It is
thought that gangliosides and membrane-bound glycoproteins may serve as
targets for toxin binding. The recent proposal that BoNT/B binds to
synaptotagmin and the gangliosides GT1b and
GD1a (16) and that BoNT/A and BoNT/E may also
bind to synaptotagmin (11) has supported this concept.
Having accomplished the first cell intoxication stage of binding, CNTs
require mechanisms to facilitate internalization into and intracellular
routing within the target cell. The actual mechanism of intracellular
routing of CNTs to the cytosol remains unclear, though the role of an acidic compartment has been proposed (10) in common with a
number of other bacterial protein toxins (20, 21). Though it
is proposed that it is the role of the HN domain to
facilitate translocation of the endopeptidase into the cytosol,
exclusion of a contribution of the HC domain in
intracellular mechanisms has not been possible. One of the aims of this
study is to address the issue of HC contribution in the
three phases of intoxication. In addition, this study aims to
investigate the ability of the HN domain to facilitate
translocation of the LC into the cytosol of both neuronal and
nonneuronal cells.
Once the CNT (or fragment) has gained access to the cytosol, the
proteolytic LCs specifically hydrolyze key components of the soluble
NSF accessory protein receptor (SNARE) complex (25) required
for synaptic vesicle docking, fusion, and neurotransmitter release. In
the case of BoNT/A and BoNT/E, the substrate is synaptosome-associated protein 25 (SNAP-25), whereas BoNT B, D, F, and G cleave the
vesicle-associated membrane protein and BoNT/C cleaves syntaxin
(2, 14). It has been demonstrated that cleavage of these
components of the SNARE complex by CNTs results in inhibition of
transmitter release from a variety of neuronal cell systems. It is also
known that formation of the SNARE complex is a universal mechanism of
vesicle fusion and secretion, not limited to neuronal cell types.
Therefore, the range of highly specific endopeptidase activities of CNT
serotypes provides an opportunity for the understanding of
SNARE-mediated events. Unfortunately, the use of native clostridial
toxins for the study of such events is often limited by the
availability of the requisite toxin receptor(s) on the target cell of
interest. Alternative approaches to internalizing the active
endopeptidase have included techniques such as microinjection,
permeabilization, and electroporation (3). However, the
invasive nature of these techniques makes them less than ideal
approaches for the study of complex intracellular processes. To
overcome these problems, and to address issues of HN and
HC domain functionality, we have sought to identify
alternative molecules capable of delivering functional endopeptidase to
the cytosol of target cells in vitro. Here we describe the replacement
of the native BoNT/A cell-binding domain (HC) with one such
alternative targeting ligand, wheat germ agglutinin (WGA), which
enables binding to a range of cell types (6).
WGA is a homodimeric lectin molecule of 36 kDa expressed by the plant
species Triticum vulgaris. WGA has an affinity for
N-acetylglucosamine (GlcNAc) and N-acetyl sialic
acid (15) and has been used previously as a neuronal cell
marker, for retrograde transport studies, and for analysis of lectin
function on a variety of cell processes (12). This profile
and the degree of characterization make WGA attractive as a novel
cell-binding domain for detoxified CNTs. In this study we report that a
WGA-LHN/A conjugate binds to, internalizes into, and
inhibits stimulated neurotransmitter release from a range of
cultured neuronal cell types. Furthermore, WGA-LHN/A conjugate is demonstrated to inhibit insulin release from a pancreatic B-cell line that is resistant to the effects of neurotoxin.
WGA-LHN/A conjugate effects on secretion are shown to be
dose dependent, mediated by ligand-dependent binding, and correlated to
cleavage of the natural BoNT/A substrate SNAP-25.
 |
MATERIALS AND METHODS |
Materials.
PC12 and SH-SY5Y cells were supplied by the
European Collection of Cell Cultures, Brighton, United Kingdom. HIT-T15
cells were kindly supplied by I. Green, University of Sussex, United Kingdom. Antibodies to SNAP-25 (SMI-81) were obtained from Sternberger Monoclonals Inc. Peroxidase-conjugated anti-species antibody was from
Stratech Scientific Ltd. Western blot detection was performed with
enhanced chemiluminescence reagents and Hyperfilm from Amersham. The
rat insulin radioimmunoassay kit was obtained from Linco Research Inc.
The protein cross-linking reagent,
N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), was
obtained from Pierce & Warriner Ltd. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) materials were
obtained from Novex. Triton X-114 was obtained from Fisons. WGA and all
other buffers, reagents, and cell culture media were obtained from
Sigma, Poole, United Kingdom.
Conjugation and purification of WGA-LHN/A.
WGA-LHN/A conjugate was synthesized by conjugating WGA and
LHN/A components that had previously been derivatized to
introduce reactive cross-linking groups. Briefly, WGA (10 mg/ml in
phosphate-buffered saline [PBS]) was reacted with an equal
concentration of SPDP (10 mM in dimethyl sulfoxide [DMSO]) for 1 h at ambient temperature. Reaction by-products were removed by
desalting into PBS over a PD-10 column (Pharmacia) prior to reduction
of the cross-linker with dithiothreitol (DTT; 5 mM for 30 min) to
generate a reactive sulfhydryl (SH) group. The thiopyridone and DTT
were then removed by desalting into PBS over a PD-10 column to result
in derivatized WGA (dWGA) with 1 mol of SH incorporated per mol of WGA.
LHN/A at a concentration of 5 mg/ml in PBSE (PBS containing
1 mM EDTA) was reacted with a fourfold molar excess of SPDP (10 mM in
DMSO). After 3 h at ambient temperature, the reaction was terminated by desalting over a PD-10 column into PBSE. To determine the
degree of derivatization, an aliquot of the derivatized
LHN/A (dLHN/A) was removed from the solution,
reduced with DTT (5 mM, 30 min), and analyzed spectrophotometrically at
280 and 343 nm.
The dWGA and the dLHN/A were mixed in a
3:1 molar ratio.
After 16 h at 4°C, the mixture was centrifuged to clear any
precipitate that had developed. The supernatant was concentrated by
ultrafiltration (Millipore Biomax Ultrafree-4; 10,000 molecular weight
exclusion limit) before application to a Superose 12 column on an FPLC
chromatography system (Pharmacia). The column was eluted with PBS, and
the elution profile was monitored at 280 nm. Fractions containing
high-molecular-weight conjugate material (separated from free dWGA)
were pooled and applied to PBS-washed GlcNAc-agarose.
WGA-LHN/A conjugate bound to the GlcNAc-agarose and was
eluted from the column by the addition of 0.3 M GlcNAc in PBS. The
elution profile was monitored at 280 nm, and fractions containing
conjugate were pooled, dialyzed against PBS, and stored at 4°C until use.
Preparation and maintenance of cell cultures.
PC12 cells
were seeded at a density of 4 × 105 cells/well onto
24-well (Matrigel coated) plates (Nunc) from stocks grown in suspension. The cells were cultured for 1 week prior to use in RPMI-1640-10% horse serum-5% fetal bovine serum-1%
L-glutamine. SH-SY5Y cells were seeded at a density of
5 × 105 cells/well onto 24-well plates (Falcon). The
cells were cultured in Ham's F-12 medium-minimal essential medium
(MEM) (1:1, vol/vol) containing 15% fetal bovine serum, 1% MEM
nonessential amino acids, and 2 mM L-glutamine for 1 week
prior to use. Embryonic spinal cord (eSC) neurons were prepared from
spinal cords dissected from 14- to 15-day-old fetal Sprague-Dawley rats
and used after 21 days in culture in a modification of a previously
described method (5, 18). HIT-T15 cells were seeded at a
density of 4 × 105 cells/well onto 12-well plates
(Falcon). The cells were cultured in RPMI-1640-5% fetal bovine
serum-2 mM L-glutamine for 5 days prior to use.
Inhibition of stimulated secretion.
PC12 or SH-SY5Y cells
were washed with a balanced salt solution (BSS: 137 mM NaCl, 5 mM KCl,
2 mM CaCl2, 4.2 mM NaHCO3, 1.2 mM
MgCl2, 0.44 mM KH2PO4, 5 mM
glucose, 20 mM HEPES [pH 7.4]) and loaded for 1 h with
[3H]noradrenaline (NA; 2 µCi/ml, 0.5 ml/well) in BSS
containing 0.2 mM ascorbic acid and 0.2 mM pargyline. Cells were washed
four times (at 15-min intervals for 1 h), and then basal release
was determined by a 5-min incubation with BSS-5 mM K+.
Cells were then depolarized with 100 mM K+ (BSS with
Na+ reduced accordingly) for 5 min to determine stimulated
release. Superfusate (0.5 ml) was removed to tubes on ice and briefly
centrifuged to pellet any detached cells. Adherent cells were
solubilized in 2 M acetic acid-0.1% trifluoroacetic acid (250 µl/well). The quantities of released and nonreleased radiolabel were
determined by liquid scintillation counting of cleared superfusates and
cell lysates, respectively. Total uptake was calculated by addition of
released and retained radioactivity, and the percentage release was as
calculated (released counts/total uptake counts) × 100.
eSC neurons were loaded with [3H]glycine for 30 min prior
to determination of basal and potassium-stimulated release of
transmitter (essentially as described before [29]). A
sample (0.2 M) of NaOH-lysed cells was used to determine total counts,
from which percent release could be calculated. Insulin release from
HIT-T15 cells was stimulated by incubation with high-potassium
Krebs-Ringer bicarbonate buffer (KRB: 103.8 mM NaCl, 5 mM
NaHCO3, 30 mM KCl, 1.2 mM KH2PO4,
1.0 mM CaCl2, 1.2 mM MgSO4, 2.8 mM glucose, 10 mM HEPES [pH 7.4]) for 30 min. Basal release was determined by identical simultaneous incubation of cells for 30 min with
low-potassium KRB (4.8 mM KCl, 129 mM NaCl). Released insulin was
determined by radioimmunoassay exactly as instructed by the manufacturer.
In vitro SNAP-25 cleavage.
The in vitro cleavage of SNAP-25
by WGA-LHN/A and other endopeptidase samples was determined
essentially as described before (8).
SDS-PAGE and Western blot analysis.
SDS-PAGE and Western
blot analyses were performed by standard protocols (Novex). SNAP-25
proteins were extracted from 2 M acetic acid-0.1% trifluoroacetic
acid-lysed cells using Triton X-114 in a method described previously
(3). The extracted proteins were resolved on a
Tris-glycine-4 to 20% polyacrylamide gel (Novex) and subsequently
transferred to a nitrocellulose membrane. The membranes were probed
with a monoclonal antibody (SMI-81) that recognizes cleaved and intact
SNAP-25. Specific binding was visualized with peroxidase-conjugated
secondary antibodies and a chemiluminescent detection system
essentially as described previously (17). Cleavage of
SNAP-25 was quantified by scanning densitometry (Molecular Dynamics
Personal SI, ImageQuant data analysis software). Percent SNAP-25
cleavage was calculated by the formula [cleaved SNAP-25/(cleaved + intact SNAP-25)] × 100.
 |
RESULTS |
Conjugation and purification of WGA-LHN/A.
Derivatization with the heterobifunctional cross-linker SPDP has been
applied successfully to both WGA and LHN/A. The
derivatization ratio of WGA was maintained at 1 introduced ---SH per
lectin dimer in order to minimize the proportion of very high molecular
weight protein aggregates. Conversely, the derivatization ratio of
LHN/A was established (observed ratio, 3.53 ± 0.59 mol of SPDP per mol of LHN/A) in order to successfully
conjugate at least one WGA per LHN/A. Conjugation of
dLHN/A with dWGA generates a heterogenous mixture of
high-molecular-weight species as determined by nonreducing SDS-PAGE
analysis (Fig. 1). However, when the
disulfide bond of the chemical linkage between LHN/A and
WGA is reduced in the presence of a thiol (5 mM DTT), the heterogenous
mixture is shown to consist of LHN/A and WGA only (Fig. 1,
lane 6).

View larger version (98K):
[in this window]
[in a new window]
|
FIG. 1.
SDS-PAGE analysis of WGA-LHN/A purification
scheme. Protein fractions were subjected to SDS-4 to 20% PAGE prior
to staining with Coomassie blue. Lanes 6 to 8 were run in the presence
of 0.1 M DTT. Lanes 1 and 7 and lanes 2 and 8 represent dWGA and
dLHN/A, respectively. Lanes 3 to 5 represent the
conjugation mixture after Superose-12 chromatography and after
GlcNAc-affinity chromatography, respectively. Lane 6 represents a
sample of reduced final material. Approximate molecular masses (in
kilodaltons) are indicated. Lanes Mr, size markers.
|
|
It was also established that the catalytic activity of the
LHN/A was not compromised by derivatization. Using a
sensitive in vitro assay that is specific for the endopeptidase
activity of BoNT/A (8), it was observed that the SPDP
derivatization reagent did not significantly decrease the endopeptidase
activity of the LHN/A. The concentrations of sample
required to achieve 50% substrate cleavage for BoNT/A,
dLHN/A, and LHN/A were determined to be of the
same order (9.0, 5.1, and 5.9 pM, respectively). Similar data (not
shown) were obtained for the WGA-LHN/A conjugate, although
since the assay is necessarily performed in the presence of a reducing
agent, these data indicate that the catalytic activity of
LHN/A has not been compromised by conjugation and
subsequent reduction. Therefore, it would be predicted that the
specific activity of the LHN/A component would be similar
to that of BoNT/A when introduced into the cell.
Purification of WGA-LHN/A was achieved by a two-step
strategy. First, size exclusion chromatography was used to remove
unconjugated WGA from the mixture, and second, an affinity
chromatography step was used to isolate and concentrate species that
bound GlcNAc. In this way, the proportion of unconjugated WGA and
LHN/A components was kept to a minimum. WGA visualized in
the purified conjugate after SDS-PAGE analysis was proposed to be due
to the dissociation of the noncovalent homodimeric WGA by SDS.
Inhibition of [3H]NA release from PC12 and SH-SY5Y
cells.
WGA-LHN/A applied to PC12 and SH-SY5Y cells was
demonstrated to result in significant inhibition of neurotransmitter
release relative to LHN/A alone. Figure
2 illustrates the neurotransmitter release data obtained following application of WGA-LHN/A
and LHN/A to PC12 and SH-SY5Y cells for 3 days. The
concentrations that inhibited activity by 50% (IC50) for
WGA-LHN/A on SH-SY5Y cells were 1.60 ± 0.06 µg/ml
(mean ± standard error of the mean, n = 3) after
3 days and 12.63 ± 3.72 µg/ml (n = 4) after
16 h of exposure. Similar data were obtained for PC12 cells
(0.63 ± 0.15 µg/ml [n = 3] after 3 days and
4.96 ± 1.13 µg/ml [n = 3] after 16 h).
In all cases the inhibitory effects of LHN/A alone were
extremely low, and IC50 data were not calculable. To
demonstrate that the observed inhibition of release was mediated by
SNAP-25 cleavage, hydrophobic proteins were isolated from
WGA-LHN/A conjugate-treated cells. The hydrophobic
proteins, including SNAP-25, were Western blotted and subsequently
probed with a primary antibody that recognizes both cleaved and
uncleaved SNAP-25. Figure 3 illustrates
the cleavage pattern obtained from one such experiment following
treatment of SH-SY5Y cells with WGA-LHN/A for 16 h.
Quantitation of the cleavage of SNAP-25 by scanning densitometry
indicated that the cleavage of SNAP-25 correlated to the inhibition of
release (Fig. 3).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Inhibition of neurotransmitter release from cultured
neuronal cells. PC12 cells (A), SH-SY5Y cells (B), and eSC neurons (C)
exposed for 3 days to a range of concentrations of
WGA-LHN/A (solid symbols) and LHN/A (open
symbols) were assessed for stimulated [3H]NA release
(SH-SY5Y and PC12 cells) or [3H]glycine release (eSC)
capability. Results are expressed as percent inhibition compared with
untreated controls. Each concentration was assessed in triplicate. For
each cell type, the dose-response curve is representative of at least
three experiments. Each point shown is the mean of at least three
determinations ± the standard error of the mean.
|
|

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 3.
Correlation of SNAP-25 cleavage with inhibition of
release. Hydrophobic proteins were extracted and probed with antibody
SMI-81 for the presence of SNAP-25 (both cleaved and uncleaved forms).
(A) Cleavage data for SH-SY5Y cells exposed to a range of
concentrations of WGA-LHN/A for 16 h. The shift to a
faster-migrating SNAP-25 species with increasing concentrations of
conjugate is clearly seen. (B) Cleavage data correlated with inhibition
of release of [3H]NA from SH-SY5Y exposed to a range of
concentrations of WGA-LHN/A for 16 h.
|
|
The retargeting of the LHN/A was further characterized by
demonstrating that the observed cell effects were mediated by
ligand-dependent targeting. SH-SY5Y cells were exposed to
WGA-LHN/A on ice (4°C) for 4 h in the presence of
various excesses of WGA, washed, and incubated for 16 h at 37°C
prior to the determination of SNAP-25 cleavage. Figure
4 clearly shows that at increased WGA
concentrations, the cleavage of SNAP-25 is decreased, and therefore the
observed endopeptidase effects are a result of WGA-mediated cell entry. These data also confirmed that SNAP-25 cleavage was not a consequence of a WGA effect on cell function.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 4.
Competition for binding of WGA-LHN/A to
SH-SY5Y cells by WGA. Cells were exposed to WGA-LHN/A (10 µg/ml) on ice for 4 h in the presence of various excesses of
WGA. The cells were washed and incubated for 16 h at 37°C prior
to the determination of SNAP-25 cleavage. SNAP-25 cleavage in the
absence of competing WGA was determined to be 63.9 ± 3.9%
(n = 3). Each point shown is the mean of at least three
determinations ± the standard error of the mean.
|
|
Inhibition of [3H]glycine release from eSC
neurons.
Primary cultures of eSC neurons are representative of in
vivo neuronal cells and are therefore relevant models for a number of
in vivo secretory processes. Since eSC neurons have been demonstrated to be sensitive to BoNT/A-dependent inhibition of secretory processes (29), they serve as a useful test model for WGA targeting.
In this study we labeled cells with [3H]glycine, an
inhibitory neurotransmitter, and therefore the stimulated release
observed represented release from an inhibitory population of neurons
in these heterogeneous cultures. Comparison of the inhibition profiles
of WGA-LHN/A and untargeted LHN/A demonstrates significant enhancement in potency (Fig. 2), with IC50s of
0.06 ± 0.01 µg/ml (n = 3) and 10.6 ± 4.9 µg/ml (n = 3) for WGA-LHN/A and
LHN/A, respectively. However, although significant potency was observed, the inhibition of release of glycine reached a plateau at
approximately 60%. The failure to achieve complete inhibition probably
relates to the substantial portion of the K+-induced
release of [3H]glycine from these cells, which has been
reported to be Ca2+ independent (28).
Ca2+ independence is not a characteristic of synaptic
release, and so it is not surprising that clostridial endopeptidases
were unable to block this component.
Comparison of inhibition of neurotransmitter release with
BoNT/A.
In order to extend this investigation into the properties
of WGA-LHN/A, we chose to include a comparison with native
neurotoxin and thus determined the IC50 of BoNT/A in the
cultured neuronal cell models. The IC50 for inhibition of
[3H]NA release from SH-SY5Y and PC12 cells were
determined to be of a similar order for both the WGA-LHN/A
conjugate and BoNT/A (Table 1). However,
in the case of eSC neurons, inhibition of [3H]glycine
release was significantly reduced in WGA-LHN/A-treated cells compared with that in BoNT/A-treated cells (Table 1). It is clear
that the WGA-LHN/A conjugate and BoNT/A do not represent proteins with identical properties of cell binding and intracellular routing.
Inhibition of insulin release from HIT-T15 cells.
The hamster
pancreatic B-cell line HIT-T15 is known to be resistant to the effects
of BoNT/A (1, 13). Previous attempts to investigate
SNARE-dependent processes in HIT-T15 cells have required
permeabilization of the cell membrane to allow the CNT endopeptidase
access to the substrate (3, 19). We have used the WGA ligand
to demonstrate that a clostridial endopeptidase can be retargeted into
the cytosol of HIT-T15 without resorting to physical disruption of the
cell membrane. HIT-T15 cells were incubated for 4 h on ice with
WGA-LHN/A and washed to remove unbound conjugate, and
insulin release was assessed by radioimmunoassay 16 h later. A
significant dose-dependent inhibition of stimulated insulin release was
observed that correlated with increasing cleavage of SNAP-25 (Fig.
5). At a concentration of 100 µg/ml,
WGA-LHN/A inhibition of insulin release was calculated to
be 81.6 ± 15.7% (n = 3), which is in good
agreement with previously reported neurotoxin-dependent inhibition of
insulin release of ~90% (3).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
WGA-LHN/A cleaves SNAP-25 and inhibits
insulin release from HIT-T15 cells. Cells were exposed to various
concentrations of WGA-LHN/A on ice for 4 h. The cells
were washed and incubated for 16 h at 37°C prior to the
determination of insulin release and SNAP-25 cleavage. Each point shown
is the mean of at least three determinations ± standard error
(release) or of two determinations (cleavage).
|
|
 |
DISCUSSION |
This study has demonstrated that LHN/A, BoNT/A which
has been enzymatically treated to remove its native cell receptor
binding domain, can be chemically derivatized without loss of
endopeptidase activity, conjugated to a second protein (WGA) to form a
stable, soluble conjugate, and delivered to a variety of cells in vitro by a ligand-dependent process to inhibit secretion in a dose-dependent manner via a mechanism involving endopeptidase-dependent cleavage of
the natural BoNT/A substrate. These data clearly demonstrate that a
hybrid protein has been created by chemically conjugating WGA and
LHN/A and that this conjugate is biologically active. Replacement of the cell-binding moiety of a number of toxins has been
reported previously (4, 27), but this work represents the
first reported replacement of the BoNT cell-binding domain to result in
the creation of a functional hybrid.
We have demonstrated internalization of functional endopeptidase into
three different neuronal cell culture models. PC12 and SH-SY5Y are well
established in vitro cell lines and neuronal models, derived from rat
adrenal chromaffin cells and human sympathetic neurons, respectively.
Both cell lines have retained the ability to release NA in a
Ca2+-dependent manner (7, 26). eSC neurons,
which are more closely representative of in vivo neuronal cells, are
exquisitely sensitive to BoNT/A (29) and contain a
population of inhibitory glycine-releasing neurons.
It is interesting that in the PC12 and SH-SY5Y cell lines,
WGA-LHN/A and BoNT/A had equivalent potency in the NA
release assays. For intracellular activity of a targeted endopeptidase,
be it native neurotoxin or a hybrid conjugate as reported here, the fundamental elements of cell surface binding, internalization, membrane
translocation, substrate localization, and endopeptidase activity must
be addressed. When comparing the potencies of native neurotoxin with
hybrid conjugates, it is likely that the efficiencies of at least one
of these elements may differ. However, the data obtained from PC12 and
SH-SY5Y cells suggest that the overall functionality of the conjugated
endopeptidase is similar to that exhibited by the native toxin
endopeptidase. Significantly, the inhibition-of-neurotransmitter-release data are supported by the in
vitro data obtained from the synthetic SNAP-25 peptide cleavage assays,
which indicated that the derivatization and conjugation procedures had
not adversely affected the LHN/A endopeptidase. Like CNT,
it would be assumed that conjugated LHN/A is required to
traverse at least one intracellular membrane to facilitate substrate
cleavage. Therefore, given the similar overall potencies of the
conjugate and BoNT/A in the PC12 and SH-SY5Y cell lines and the
equivalent catalytic activity of the LHN/A endopeptidase, it would appear that the membrane translocation functions of the LHN/A have not been significantly compromised by chemical
manipulation. Indeed, these observations suggest that the
HN domain is fully effective at transporting LC into the
cytosol, even though the receptor-mediated mode of entry is different
from that encountered during neurointoxication. Thus, it is concluded
that the HN domain has the ability to facilitate
translocation of the LC in cell types not associated with the
neuromuscular junction. In addition, the lack of potency of
LHN/A in all three cell types confirms previous data
(22) that described the removal of cell-binding ability from
BoNT/A by proteolytic removal of the HC domain by trypsin
treatment. Therefore, the data obtained with novel conjugates demonstrate that the function of the HC domain of BoNT/A is
limited to cell-binding events and exclude a significant role in the
intracellular mechanisms of intoxication. The use of a novel binding
domain to deliver the LHN fragment to a neuronal cell is
one of the few ways that this proposed domain functionality could be
experimentally verified.
Furthermore, we have demonstrated internalization of functional
endopeptidase into an endocrine cell line, HIT-T15. Inhibition of
Ca2+-dependent insulin release was correlated to the
cleavage of SNAP-25, and the inhibition of insulin release attained
following application of WGA-LHN/A was similar to that
previously reported for BoNT/A-treated cells (3), in which
permeabilization of the cell membrane was required for toxin entry. It
is interesting that the concentration of WGA-LHN/A
conjugate (approximately 500 nM) applied to the cells in this study to
achieve >80% inhibition was similar to the concentration of BoNT/A
used in the previous study (3). These data indicate that the
WGA moiety leads to internalization of the endopeptidase component of
the conjugate into an intracellular compartment from which the
endopeptidase can efficiently translocate. The effective functioning of
the LC in the HIT-T15 cytosol, as evidenced by the cleavage of SNAP-25
and inhibition of insulin secretion, also demonstrates that the
HN domain is able to function in a nonneuronal environment,
enabling translocation of the LC. This is the first demonstration of
such an HN function in a nonneuronal cell. The ability to
inhibit SNARE-dependent release from a cell that is resistant to the
actions of surface-applied neurotoxin is a significant step forward in
the design of a tool for investigation of SNARE-mediated processes. In
addition, these data are instrumental in defining the specific binding
characteristics of the HC domain as being the major factor
in susceptibility of cells to intoxication by BoNT.
This study has also indicated differences in potency between the
WGA-LHN/A conjugate and intact BoNT/A. The susceptibility of the established cell lines and eSC neuron cells to BoNT/A-dependent inhibition of transmitter release varies markedly (Table 1), with eSC
neurons being greater than 105-fold more sensitive than
PC12 and SH-SY5Y cells. This difference could possibly be due to the
prevalence of the requisite receptor for BoNT/A on the plasma membrane
and/or the concentration of SNAP-25 near the point of internalization.
As described above, WGA-LHN/A exhibited potency similar to
BoNT/A when applied to PC12 and SH-SY5Y cells. However,
WGA-LHN/A did not result in inhibition of neurotransmitter
release in eSC neurons similar to that determined for BoNT/A and was
shown to have an IC50 at least 13,000-fold greater than
BoNT/A. Therefore, these data indicate that, although a conjugate of
significant potency has been engineered, the binding, and possibly the
intracellular routing, characteristics of the conjugate do not
represent regeneration of the parental neurotoxin. This is further
evidenced by the activity of the conjugate in HIT-T15 cells, in which
BoNT/A is ineffective.
The documented cell-binding and internalization characteristics of WGA
(30) were instrumental in its choice as a suitable ligand
for LHN/A targeting. We have demonstrated the functionality of a conjugate prepared between this broad-specificity targeting ligand
and a clostridial endopeptidase. We have demonstrated that WGA can
serve as an efficient targeting vehicle, thereby expanding the
repertoire of cells that can be studied with native BoNT/A to those
that lack the native BoNT/A receptor(s), including, for the first time,
nonneuronal cells. The novel cell-binding abilities of such hybrid
targeted endopeptidases provide a powerful tool for the investigation
of secretory and vesicle fusion mechanisms in a variety of cell systems
and membrane fusion pathways. We have also demonstrated that the
HN and HC domains of the BoNT/A HC do have
defined roles in translocation and membrane binding, respectively, and
that the exquisite potency of CNTs is, in major part, due to specific
binding to the target cell. The observation that the HN
domain is fully capable of effecting translocation of LC in a variety
of cells indicates that HC is a very effective targeting
moiety for a very effective toxin. The challenge of toxin research is
to use our greater understanding of toxin biology to lead to a greater
understanding of cellular events.
 |
ACKNOWLEDGMENT |
We are grateful to F. Alexander for supplying purified BoNT/A.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centre for
Applied Microbiology & Research, Porton Down, Salisbury, Wiltshire SP4
0JG, United Kingdom. Phone: 01980 612733. Fax: 01980 611310. E-mail: john.chaddock{at}camr.org.uk.
Present address: Office of Science and Technology, Albany House,
London SW1P 9ST, United Kingdom.
Editor:
J. T. Barbieri
 |
REFERENCES |
| 1.
|
Black, J. D., and J. O. Dolly.
1987.
Selective localisation of acceptors for botulinum neurotoxin A in the central and peripheral nervous systems.
Neuroscience
23:767-779[CrossRef][Medline].
|
| 2.
|
Blasi, J.,
E. R. Chapman,
E. Link,
T. Binz,
S. Yamasaki,
P. De Camilli,
T. C. Sudhof,
H. Niemann, and R. Jahn.
1993.
Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.
Nature
365:160-163[CrossRef][Medline].
|
| 3.
|
Boyd, R. S.,
M. J. Duggan,
C. C. Shone, and K. A. Foster.
1995.
The effect of botulinum neurotoxins on the release of insulin from the insulinoma cell lines HIT-15 and RINm5F.
J. Biol. Chem.
270:18216-18218[Abstract/Free Full Text].
|
| 4.
|
Fitzgerald, D.,
V. K. Chaudhary,
R. J. Kreitman,
C. B. Siegall, and I. Pastan.
1992.
Generation of chimeric toxins.
Targeted Diagn. Ther.
7:447-462[Medline].
|
| 5.
|
Fitzgerald, S. C.
1989.
A dissection and tissue culture manual of the nervous system.
Alan R. Liss, Inc., New York.
|
| 6.
|
Gabor, F.,
M. Stangl, and M. Wirth.
1998.
Lectin-mediated bioadhesion: binding characteristics of plant lectins on the enterocyte-like cell lines Caco-2, HT-29 and HCT-8.
J. Controlled Release
55:131-142[CrossRef][Medline].
|
| 7.
|
Greene, L. A., and A. S. Tischler.
1982.
PC12 pheochromocytoma cultures in neurobiological research, p. 373-414.
In
S. Federoff, and L. Hertz (ed.), Advances in cellular neurobiology, vol. 3. Academic Press, New York.
|
| 8.
|
Hallis, B.,
B. A. F. James, and C. C. Shone.
1996.
Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.
J. Clin. Microbiol.
34:1934-1938[Abstract].
|
| 9.
|
Halpern, J. L., and E. A. Neale.
1995.
Neurospecific binding, internalization, and retrograde axonal transport.
Curr. Top. Microbiol. Immunol.
195:221-241[Medline].
|
| 10.
|
Hoch, D. H.,
M. M. Romero,
B. E. Ehrlich,
A. Finkelstein,
B. R. DasGupta, and L. L. Simpson.
1985.
Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes.
Proc. Natl. Acad. Sci. USA
82:1692-1696[Abstract/Free Full Text].
|
| 11.
|
Li, L., and B. R. Singh.
1998.
Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay.
J. Nat. Toxins
7:215-226[Medline].
|
| 12.
|
Lis, H., and N. Sharon.
1986.
Lectins as molecules and as tools.
Annu. Rev. Biochem.
55:35-67[CrossRef][Medline].
|
| 13.
|
Montecucco, C.
1986.
How do tetanus and botulinum toxins bind to neuronal membranes?
Trends Biochem. Sci.
11:314-317[CrossRef].
|
| 14.
|
Montecucco, C., and G. Schiavo.
1994.
Mechanism of action of tetanus and botulinum neurotoxins.
Mol. Microbiol.
13:1-8[Medline].
|
| 15.
|
Nagata, Y., and M. M. Burger.
1974.
Wheat germ agglutinin: molecular characteristics and specificity for sugar binding.
J. Biol. Chem.
249:3116-3122[Abstract/Free Full Text].
|
| 16.
|
Nishiki, T.,
Y. Kamata,
Y. Nemoto,
A. Omori,
T. Ito,
M. Takahashi, and S. Kozaki.
1994.
Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes.
J. Biol. Chem.
269:10498-10503[Abstract/Free Full Text].
|
| 17.
|
Oyler, G. A.,
G. A. Higgins,
R. A. Hart,
E. Battenberg,
M. Billingsley,
F. E. Bloom, and M. C. Wilson.
1989.
The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations.
J. Cell Biol.
109:3039-3052[Abstract/Free Full Text].
|
| 18.
|
Ransom, B. R.,
E. Neale,
M. Henkart,
P. N. Bullock, and P. G. Nelson.
1977.
Mouse spinal cord in cell culture. I. Morphology and intrinsic neuronal electrophysiologic properties.
J. Neurophysiol.
40:1132-1150[Abstract/Free Full Text].
|
| 19.
|
Sadoul, K.,
J. Lang,
C. Montecucco,
U. Weller,
R. Regazzi,
S. Catsicas,
C. B. Wollheim, and P. A. Halban.
1995.
SNAP-25 is expressed in islets of Langerhans and is involved in insulin release.
J. Cell Biol.
128:1019-1028[Abstract/Free Full Text].
|
| 20.
|
Saleh, M. T., and J. Gariepy.
1993.
Local conformational change in the B-subunit of Shiga-like toxin 1 at endosomal pH.
Biochemistry
32:918-922[CrossRef][Medline].
|
| 21.
|
Sandvig, K., and S. Olsnes.
1980.
Diphtheria toxin entry into cells is facilitated by low pH.
J. Cell Biol.
87:828-832[Abstract/Free Full Text].
|
| 22.
|
Shone, C. C.,
P. Hambleton, and J. Melling.
1987.
A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles.
Eur. J. Biochem.
167:175-180[Medline].
|
| 23.
|
Shone, C. C.,
P. Hambleton, and J. Melling.
1985.
Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments: proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity.
Eur. J. Biochem.
151:75-82[Medline].
|
| 24.
|
Simpson, L. L.
1981.
The origin, structure, and pharmacological activity of botulinum toxin.
Pharmacol. Rev.
33:155-188[Medline].
|
| 25.
|
Sollner, T.,
S. W. Whiteheart,
M. Brunner,
H. Erdjument Bromaga,
S. Geromanos,
P. Tempst, and J. E. Rothman.
1993.
SNAP receptors implicated in vesicle targeting and fusion.
Nature
362:318-324[CrossRef][Medline].
|
| 26.
|
Vaughan, P. F. T.,
C. Peers, and J. H. Walker.
1995.
The use of the human neuroblastoma SH-SY5Y to study the effect of second messengers on noradrenaline release.
Gen. Pharmacol.
26:1191-1201[Medline].
|
| 27.
|
Williams, D. P.,
K. Parker,
P. Bacha,
W. Bishai,
M. Borowski,
F. Genbauffe,
T. B. Strom, and J. R. Murphy.
1987.
Diphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion protein.
Protein Eng.
1:493-498[Abstract/Free Full Text].
|
| 28.
|
Williamson, L.,
S. C. Fitzgerald, and E. A. Neale.
1992.
Differential effects of tetanus toxin on inhibitory and excitatory neurotransmitter release from mammalian spinal cord cells in culture.
J. Neurochem.
59:2148-2157[Medline].
|
| 29.
|
Williamson, L. C.,
J. L. Halpern,
C. Montecucco,
J. E. Brown, and E. A. Neale.
1996.
Clostridial neurotoxins and substrate proteolysis in intact neurons.
J. Biol. Chem.
271:7694-7699[Abstract/Free Full Text].
|
| 30.
|
Wirth, M.,
A. Fuchs,
M. Wolf,
B. Ertl, and F. Gabor.
1998.
Lectin-mediated drug targeting: preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells.
Pharm. Res.
15:1031-1037[CrossRef][Medline].
|
Infection and Immunity, May 2000, p. 2587-2593, Vol. 68, No. 5
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Duggan, M. J., Quinn, C. P., Chaddock, J. A., Purkiss, J. R., Alexander, F. C. G., Doward, S., Fooks, S. J., Friis, L. M., Hall, Y. H. J., Kirby, E. R., Leeds, N., Moulsdale, H. J., Dickenson, A., Green, G. M., Rahman, W., Suzuki, R., Shone, C. C., Foster, K. A.
(2002). Inhibition of Release of Neurotransmitters from Rat Dorsal Root Ganglia by a Novel Conjugate of a Clostridium botulinum Toxin A Endopeptidase Fragment and Erythrina cristagalli Lectin. J. Biol. Chem.
277: 34846-34852
[Abstract]
[Full Text]